Second TB biomarker identified

The Biomagnetics Diagnostic Corporation has announced the identification of a second biomarker for developing a tuberculosis assay that may help in faster detection of tuberculosis by inexperienced personnel outside of a laboratory setting.

The identification comes on the heels of a cooperative research agreement signed between Biomagnetics and the Los Alamos National Laboratory, which represented a major step in developing a new point-of-care diagnostic system.

Biomagnetics also said that it is developing assays for two different tuberculosis biomarkers and the cholera toxin.

“The hand-held version of the Integrated Optical Biosensor, being developed by Biomagnetics, is specifically designed to be field deployable and ultraportable, allowing for the rapid detection of various pathogens by relatively untrained personnel outside the laboratory setting, at a lower cost than traditional diagnostic technologies,” Clayton Hardman, CEO of Biomagnetics, said. “We believe these devices hold the potential to revolutionize disease detection, saving millions of lives in the process. We are clearly honored to be working with the very prestigious and highly qualified scientific staff at Los Alamos National Laboratory.”

Biomagnetics Diagnostics Corporation is currently developing diagnostic systems and technology for hepatitis, cholera, malaria, HIV and tuberculosis detection, along with other potentially innovative technologies, such as waveguide-based advanced integrated optical biosensors.